Drug Updates

There is an urgent unmet need for more effective therapies in pancreatic cancer.
This therapy is indicated for the treatment of adults and children with hepatic veno-occlusive disease (VOD) who develop renal or pulmonary dysfunction after undergoing hematopoietic SCT.
Lung cancer is the leading cause of cancer-related mortality in the United States among men and women. The most common type of the disease, non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases.
Sugammadex (Bridion) injection has been approved for use by the US Food and Drug Administration to reverse the effects of neuromuscular blockade drugs (rocuronium bromide and vecuronium bromide) used during tracheal intubation in adult patients. This injection may help patients recover from these drugs sooner.
Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 231,840 American women will be diagnosed with breast cancer, and nearly 40,300 women will die from the disease in 2015.
An examination of the Sur-veillance, Epidemiology and End Results (SEER)-Medicare database from 1998 through 2008 revealed that a significant number of patients with cancer received unapproved drugs...
Recent surveys of oncologists and hematologists show that drug shortages persist, that practitioners are adapting in ways that often raise the cost of cancer care, and that most have no guidance to aid in decision making in the face of these shortages.
This is the third article in a 4-part series on bendamustine. While the previous article discussed the efficacy of bendamustine for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in the registration studies cited in the US product labeling, this article discusses its safety
Bendamustine is an active chemotherapy agent approved by the FDA for the treatment of patients with chronic lymphocytic leukemia (CLL) and for specific populations of patients with non-Hodgkin lymphoma (NHL).
Bendamustine is approved for single-agent use in chronic lymphocytic leukemia (CLL) based on the result from a phase 3 trial comparing bendamustine and chlorambucil.
Page 2 of 3
Results 11 - 20 of 25